Schrödinger Selects Sapio Sciences to Enhance In Silico Drug Discovery from Plasmid to Structure
Configurable informatics platform improves lab efficiency, data tracking, and resource management from plasmid to structure
BALTIMORE, January 28, 2025--(BUSINESS WIRE)--Sapio Sciences, the science-aware™ lab informatics platform, today announced that Schrödinger, a global leader in computational chemistry, has adopted the Sapio Platform to improve data management, enhance lab efficiency, and accelerate the discovery of novel molecules. By deploying Sapio's unified informatics platform, including Sapio LIMS and Sapio ELN, Schrödinger is transforming its recently acquired wet lab operations, integrating data, and streamlining workflows.
Schrödinger established its internal wet lab after acquiring a contract research organization (CRO) in 2021. However, the lab's reliance on manual, paper-based processes posed significant challenges in scalability, traceability, and operational efficiency. Transitioning to Sapio's no-code informatics platform has provided a scalable, flexible solution that simplifies operations and accelerates scientific progress.
Dr. Rajesh Kumar, Senior Director of Drug Discovery at Schrödinger, commented: "Sapio's solution has allowed us to digitize critical lab functions, improve efficiency, and ensure seamless sample traceability across our research and discovery processes. By unifying data and automating workflows, we're able to focus on advancing our research with greater speed and confidence."
Since adopting the Sapio Platform, Schrödinger has realized several key benefits, including:
Improved visibility across the discovery process: Researchers now have a clear, real-time view of every stage, optimizing resource use and improving overall efficiency.
Comprehensive data traceability: Detailed documentation of lab activities simplifies audits, accelerates regulatory filings, and ensures full compliance.
Optimized resource allocation: Access to historical data enables better planning, budgeting, and distribution of resources across multiple projects.
Long-term knowledge retention: A centralized knowledge base allows scientists to easily retrieve critical data, supporting ongoing and future research initiatives.
Mike McCartney, Chief Commercial Officer at Sapio Sciences, commented: "Schrödinger's adoption of the Sapio Platform highlights the increasing demand for configurable informatics solutions that unify complex lab environments. By eliminating data silos and improving lab efficiency, we're enabling Schrödinger to accelerate drug discovery and drive innovation."
The full story on the Schrödinger implementation can be found here.
About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 900 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com.
About Sapio Sciences
At Sapio Sciences, our mission is to improve lives by accelerating discovery and diagnostics. Our cloud-based solutions—LIMS, ELN, and Scientific Data Management—are unified on a flexible, configurable, and AI-powered informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing.
Trusted by global leaders and innovators worldwide, we support a wide range of best-in-class applications, from NGS genomic sequencing and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies.
Discover how Sapio Sciences can revolutionize your lab operations at www.sapiosciences.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250128467783/en/
Contacts
For further information, please contact: Zyme Communications Anna BakewellTel: +44 (0)7801 098 242Email: anna.bakewell@zymecommunications.com
Tim BrookHead of PR, Sapio SciencesTel: +44 (0)7760 766 213Email: press@sapiosciences.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12-06-2025
- Yahoo
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress
SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed across a broad range of B-cell malignancies, including monotherapy responses in patients with CLL and Waldenström macroglobulinemia Management to host a webcast today at 8:00 a.m. ET MILAN, June 12, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies. SGR-1505 was observed to be safe, well tolerated, and clinically active, with responses observed in multiple histologies, including in patients with chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM). These data are being presented in a poster presentation at the European Hematology Association Annual Congress. "We are very encouraged by the initial results from our Phase 1 study in patients with relapsed/refractory B-cell malignancies. The data presented today, coupled with the differentiated preclinical and safety profiles observed in our previously completed study in healthy volunteers, further increases our conviction about the potential for SGR-1505 to be a best-in-class therapy," said Margaret Dugan, M.D., chief medical officer at Schrödinger. "Dose escalation is complete, and we look forward to discussing these results and our proposed recommended Phase 2 dose with the FDA later this year." "Despite recent advances in the treatment of B-cell malignancies, resistance to currently available therapies eventually results in treatment failure and disease progression for many patients," said Stephen Spurgeon, M.D., Associate Professor of Medicine, Oregon Health and Science University, and an investigator for the clinical study. "We know that MALT1 plays a critical role in key signaling pathways that drive cancer cell survival and proliferation, making it a promising target for a broad range of B-cell malignancies. Although these data are from an early-phase study, they suggest SGR-1505 demonstrates on-target activity resulting in potential clinical benefit. I look forward to seeing additional data as the study progresses, including response data in patients with aggressive histologies." "The positive data reported today represent a key milestone for Schrödinger and follow the clinical successes of programs advanced by collaboration partners and companies we have co-founded," said Karen Akinsanya, Ph.D., president, head of therapeutics R&D and chief strategy officer, partnerships at Schrödinger. "These data reinforce the power of Schrödinger's platform to enable the rapid design of differentiated molecules and the impact that our computational approach can have on a drug discovery and development program." Major Takeaways from the Study As of the data cut-off date, May 13, 2025, 49 patients were enrolled and evaluable for safety, including 18 patients with CLL/SLL, nine with diffuse large B-cell lymphoma (DLBCL), six with Waldenström macroglobulinemia (WM), and five with marginal zone lymphoma (MZL). Patients had a median of four (range two-nine) prior lines of therapy, with the most common being Bruton's tyrosine kinase (BTK) inhibitors (55.1%), BCL-2 inhibitors (18.4%) and BTK+BCL-2 inhibitors (18.4%). SGR-1505 was well-tolerated with no dose-limiting toxicities or deaths due to treatment-emergent adverse events (TEAEs). Forty three percent of patients (n=21) experienced ≥ 1 treatment-related adverse event (TRAE), with the most common (≥ 10%) being rash (12%) and fatigue (12%). Ten patients (20%) experienced treatment-emergent serious adverse events (SAEs); one was treatment-related. All blood bilirubin increased TEAEs were asymptomatic, reported in patients with UGT1A1 polymorphisms and none were Grade 4. Inhibition of IL-2 is a pharmacodynamic biomarker for target engagement and an exploratory endpoint in the study. Preliminary data indicated that SGR-1505 inhibits T-cell derived IL-2 upon ex vivo stimulation achieving the PD target of ~90% inhibition in the majority of PD-evaluable participants treated at ≥ 150 mg QD and all Q12H doses at steady state. Preliminary efficacy data indicated SGR-1505 was clinically active as a monotherapy in a number of relapsed/refractory B-cell malignancies. Of the 49 participants, 45 patients had at least one follow-up disease assessment or disease progression and were evaluable for preliminary efficacy. The overall response rate (ORR) across all dose levels was 22% (n = 10/45). Thirteen of 49 patients had been on treatment for ≥120 days. Among patients with indolent disease, 3/17 CLL/SLL, 5/5 WM, and 1/5 MZL patients responded. The responses of the three CLL responders were independently reviewed and confirmed, and two had a partial response (PR) with lymphocytosis (PR-L). Two of three CLL patients with partial responses were double-exposed to BTK and BCL-2 inhibitors, and all WM patients were exposed to BTK inhibitors. The study recently began enrolling patients with aggressive lymphomas into the 300 mg QD and 100 mg Q12H cohorts. A PR was reported in one of four ABC-DLBCL patients. Study DesignThe Phase 1 dose-escalation study (NCT05544019) assessed SGR-1505 as a monotherapy treatment in patients with relapsed/refractory B-cell malignancies. The primary endpoint is the incidence and severity of adverse events and dose-limiting toxicities. Secondary endpoints include pharmacokinetic and pharmacodynamic measurements as well as objective response rate, duration of response and disease control rate. EHA Poster Presentation DetailsThe full abstract (#PS1569) can be found online at Poster Title: A Phase 1 study of SGR-1505, an oral, potent, MALT1 inhibitor for relapsed/refractory (R/R) B-cell malignancies, including chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL)Presentation Date and Time: Saturday, June 14, 2025, 6:30-7:30PM CST (12:30-1:30PM ET)Location: Poster Session 2 About SGR-1505SGR-1505 is an oral investigational MALT1 inhibitor being evaluated for the treatment of relapsed/refractory B-cell malignancies. MALT1 plays a central role in key signaling pathways that drive cancer cell survival and proliferation, making its location downstream of BTK in the NF-κB signaling pathway an attractive target for the development of novel therapeutics for a potentially broad range of B-cell malignancies. In preclinical studies, SGR-1505 was observed to be highly potent and selective, and has demonstrated anti-tumor activity in preclinical models both as a monotherapy and in combination with BTK and BCL-2 inhibitors. There is also emerging therapeutic rationale supporting MALT1 inhibition as a potential treatment for inflammatory and autoimmune disorders. SGR-1505 was designed using Schrödinger's computational platform at scale and was discovered approximately 10 months after the company started its MALT1 program. Schrödinger believes that SGR-1505 is currently the most advanced MALT1 inhibitor known to be in clinical development and has both first-in-class and best-in-class potential. A Phase 1 study in patients with relapsed/refractory B-cell malignancies is ongoing (NCT05544019). Webcast and Conference Call InformationSchrödinger will host a conference call on Thursday, June 12, 2025, at 8:00 a.m. ET to review the clinical opportunity for SGR-1505 and review the Phase 1 data presented at EHA. The live webcast can be accessed under "Events & Presentations" in the investors section of Schrödinger's website, To participate in the live call, please register for the call here. It is recommended that participants register at least 15 minutes in advance of the call. The archived webcast will be available on Schrödinger's website for approximately 90 days following the event. About SchrödingerSchrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn and Instagram, or visit our blog, Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding the potential advantages of Schrödinger's computational platform, the clinical potential and favorable properties of SGR-1505, its MALT1 inhibitor, and the potential for SGR-1505 to be used for the treatment of relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic leukemia, and Waldenström macroglobulinemia, and Schrödinger's plans to engage with regulators. Statements including words such as "aim," "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goal," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger's current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schrödinger's control, including the uncertainties inherent in drug development and commercialization, such as the conduct of research activities and the timing of and its ability to initiate and complete preclinical studies and clinical trials, whether results from preclinical and early clinical studies will be predictive of the results of later preclinical studies and clinical trials, whether initial data from clinical results will be predictive of the final results of the clinical trials, uncertainties associated with the regulatory review of clinical trials and applications for marketing approvals and the ability to retain and hire key personnel on its business and other risks detailed under the caption "Risk Factors" and elsewhere in the company's Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 7, 2025, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schrödinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise. View source version on Contacts Matthew Luchini (Investors) 917-719-0636Allie Nicodemo (Media) 617-356-2325 Sign in to access your portfolio
Business Wire
29-05-2025
- Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company's newly appointed EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing, Mannix Aklian. As previously announced, Mr. Aklian joined the company on May 28, 2025. The grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, effective as of May 29, 2025, and were made as a material inducement to Mr. Aklian's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation. The inducement grants consisted of a non-statutory stock option to purchase 84,375 shares of the company's common stock and restricted stock units (RSUs) with respect to 14,063 shares of the company's common stock. The stock option has an exercise price of $21.44 per share, equal to the closing price of the company's common stock on May 29, 2025. The stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when Mr. Aklian completes 12 months of continuous service measured from his employment start date, and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon Mr. Aklian's completion of each additional month of service over the 36-month period following the first anniversary of his employment start date, subject to continued service. The RSUs vest over four years, with 25 percent of such RSUs vesting when Mr. Aklian completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon Mr. Aklian's completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn, or visit our blog,
Yahoo
29-05-2025
- Yahoo
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
NEW YORK, May 29, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company's newly appointed EVP, Chief Commercial Officer, Global Head of Software Sales & Marketing, Mannix Aklian. As previously announced, Mr. Aklian joined the company on May 28, 2025. The grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, as amended, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, effective as of May 29, 2025, and were made as a material inducement to Mr. Aklian's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation. The inducement grants consisted of a non-statutory stock option to purchase 84,375 shares of the company's common stock and restricted stock units (RSUs) with respect to 14,063 shares of the company's common stock. The stock option has an exercise price of $21.44 per share, equal to the closing price of the company's common stock on May 29, 2025. The stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when Mr. Aklian completes 12 months of continuous service measured from his employment start date, and the balance of the shares vesting in a series of successive equal monthly installments of 1/48 of the original number of shares upon Mr. Aklian's completion of each additional month of service over the 36-month period following the first anniversary of his employment start date, subject to continued service. The RSUs vest over four years, with 25 percent of such RSUs vesting when Mr. Aklian completes 12 months of continuous service measured from the vesting commencement date, and the balance of the RSUs vesting in a series of successive equal yearly installments of 1/4 of the original number of RSUs upon Mr. Aklian's completion of each additional year of service over the three-year period following the first anniversary of the vesting commencement date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit follow us on LinkedIn, or visit our blog, View source version on Contacts Investor contact: Allie Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
